Voyager Therapeutics’ (VYGR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report published on Thursday,Benzinga reports. HC Wainwright currently has a $30.00 target price on the stock.

A number of other brokerages have also recently issued reports on VYGR. Citigroup assumed coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price for the company. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Wedbush reiterated an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $14.86.

Voyager Therapeutics Price Performance

Shares of NASDAQ:VYGR opened at $3.90 on Thursday. The company’s fifty day moving average price is $4.83 and its 200 day moving average price is $5.82. Voyager Therapeutics has a 12 month low of $3.56 and a 12 month high of $10.66. The firm has a market capitalization of $213.04 million, a P/E ratio of 5.49 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $4.39 million for the quarter, compared to analysts’ expectations of $16.58 million. During the same period in the previous year, the business posted $1.25 earnings per share. On average, sell-side analysts anticipate that Voyager Therapeutics will post -0.91 EPS for the current year.

Insiders Place Their Bets

In other news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 10,778 shares of company stock valued at $58,548. Company insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in Voyager Therapeutics by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after buying an additional 6,740 shares in the last quarter. FMR LLC boosted its position in shares of Voyager Therapeutics by 26.9% during the 3rd quarter. FMR LLC now owns 92,498 shares of the company’s stock valued at $541,000 after purchasing an additional 19,622 shares in the last quarter. Barclays PLC lifted its stake in Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after buying an additional 37,398 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Voyager Therapeutics by 23.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock valued at $223,000 after buying an additional 7,573 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Voyager Therapeutics by 3.4% in the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock worth $405,000 after purchasing an additional 2,354 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.